Sanofi-aventis and Regeneron Pharmaceuticals, Inc. have updated the clinical development program for aflibercept, and provided results from a Phase II study in advanced ovarian cancer. The companies reported that a recent study did not achieve its primary endpoint of demonstrating that patients in either arm of the study achieved a RECIST (Response Evaluation Criteria in Solid Tumors) response rate that was statistically significant.     The two companies are now enrolling approximately 4,000...